Literature DB >> 6277546

Ceftizoxime kinetics and renal handling.

J Dubb, P Actor, D Pitkin, F Alexander, R Familiar, S Ehrlich, R Stote.   

Abstract

The kinetics and renal handling of ceftizoxime were examined after intravenous and intramuscular injection and the effect of probenecid on its excretion was investigated. Peak serum level after 1000 mg IV was 60.5 microgram/ml and half-life (t 1/2) was 1.4 hr. Peak serum level (40.9 microgram/ml) was reached 1 hr after 1000 mg IM. When probenecid was added to the 1000-mg IM dose the peak level was 44.3 microgram/ml at 1 hr and serum levels at 2, 4, 6, and 8 hr were all higher than after ceftizoxime alone (P less than 0.01). The 1.85-hr t 1/2 of ceftizoxime alone was extended to 2.29 hr when probenecid was added. Ceftizoxime was shown to be actively secreted by the renal tubule; this secretion was decreased by probenecid.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277546     DOI: 10.1038/clpt.1982.69

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Pharmacokinetics of cefmetazole administered intramuscularly and intravenously to healthy adults.

Authors:  J Rodriguez-Barbero; E L Mariño; A Dominguez-Gil
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

2.  Pharmacokinetics of ceftizoxime.

Authors:  U Gundert-Remy; R Hildebrandt; A Stiehl; P Schlegel
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Pharmacokinetics, protein binding, and extravascular distribution of ceftizoxime in normal subjects.

Authors:  L R Peterson; D N Gerding; L L Van Etta; J H Eckfeldt; T A Larson
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 4.  Cephalosporin-probenecid drug interactions.

Authors:  G R Brown
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

5.  Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate.

Authors:  L Maass; V Malerczyk; M Verho; P Hajdú; K Seeger; N Klesel
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

Review 6.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 7.  Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R C Heel
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.